Adult Intraventricular Hemorrhage Market Report 2024

The adult intraventricular hemorrhage market size has grown strongly in recent years. It will grow from $1.97 billion in 2023 to $2.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to advancements in neuroimaging techniques, an increase in hypertension and cardiovascular diseases, the growing elderly population, rising incidents of traumatic brain injuries, and innovations in medical technology.

The adult intraventricular hemorrhage market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to innovations in minimally invasive surgical techniques, enhanced healthcare infrastructure, increased focus on stroke prevention and management, development of new pharmacological treatments, and growing awareness and education programs. Major trends during this period include the rise of telemedicine and remote monitoring, development of targeted therapies, expansion of comprehensive stroke centers, enhanced rehabilitation services, and a shift toward personalized medicine.

The anticipated rise in strokes is expected to drive growth in the adult intraventricular hemorrhage (IVH) market. A stroke, a critical medical condition resulting from interrupted blood flow to the brain causing brain cell damage, contributes significantly to the incidence of adult IVH. Factors such as an aging population, increasing rates of hypertension, diabetes, and obesity, along with lifestyle-related risks such as smoking and physical inactivity, are primary drivers of the increasing stroke incidence. Adult IVH occurs when bleeding within the brain's ventricular system is triggered by ruptured blood vessels. For example, according to the Australian Bureau of Statistics, there were 9,300 doctor-certified deaths due to cerebrovascular diseases, including stroke, in both 2021 and 2022, marking a 2.2% increase from 2020. This reversal of a historical decline underscores the growing impact of strokes on adult IVH, thereby propelling market growth.

Leading companies in the adult intraventricular hemorrhage market are focusing on innovative product development, particularly neuroaccess devices for managing both ischemic and hemorrhagic strokes. These devices are essential tools used to access the brain or spinal cord for diagnostic and therapeutic procedures in neurovascular management. For instance, Penumbra Inc., a US-based medical device company, introduced its BMX81 and BMX96 neuroaccess devices in June 2024, following CE Mark approval for the European market. These advanced devices utilize laser-cut stainless steel hypo tube technology to enhance stability and trackability, enabling physicians to navigate the complex anatomy of the brain effectively.

In August 2022, Medtronic plc, an Ireland-based healthcare company, acquired Affera Inc., a US-based provider of catheters for adult intraventricular hemorrhage, to bolster its portfolio of diagnostic and therapeutic tools. This strategic move strengthens Medtronic's market position in offering comprehensive solutions for managing strokes and related conditions.

Major companies operating in the adult intraventricular haemorrhage market are Johnson and Johnson, Abbott Laboratories, Medtronic Plc, Siemens Healthineers, Medline Industries, Philips Healthcare Inc., Stryker Corporation, GE HealthCare Technologies Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, B. Braun Melsungen AG, Alcon Inc., Zimmer Biomet Holdings Inc., Olympus Corporation, Smith and Nephew, Kaneka Corporation, Karl Storz SE and Co. KG, Carl Zeiss Meditec AG, Integra Lifesciences Holdings Corp, Elekta AB, Leica Microsystems GmbH, KLS Martin Group, Natus Medical Incorporated, Aesculap Inc., NeuroPace Inc., Sophysa USA Inc, Spiegelberg GmbH and Co. KG, Vivonics Inc.

North America was the largest region in the adult intraventricular hemorrhage market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult intraventricular haemorrhage market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adult intraventricular haemorrhage market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adult intraventricular hemorrhage (IVH) is a type of bleeding that occurs within the brain's ventricular system, where cerebrospinal fluid is produced and circulates. It often results from trauma, stroke, or other conditions that cause blood vessels in the brain to rupture. IVH can lead to increased intracranial pressure, hydrocephalus, and neurological damage, requiring prompt medical intervention.

The main product types for managing adult intraventricular hemorrhage include surgical devices, drugs, and monitoring devices. Surgical devices are specialized tools or instruments used during surgeries to perform specific actions or achieve certain outcomes in medical procedures. These products are distributed through various channels, such as direct sales, distributors, online platforms, and others. They are used in various applications, including intraventricular hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, and others. The end-users of these products include hospitals, specialty clinics, ambulatory surgical centers, diagnostic centers, and others.

The adult intraventricular hemorrhage market research report is one of a series of new reports that provides adult intraventricular hemorrhage market statistics, including adult intraventricular hemorrhage industry global market size, regional shares, competitors with a adult intraventricular hemorrhage market share, detailed adult intraventricular hemorrhage market segments, market trends and opportunities, and any further data you may need to thrive in the adult intraventricular hemorrhage industry. This adult intraventricular hemorrhage market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult intraventricular hemorrhage market consists of revenues earned by entities by providing services such as neurological assessment and monitoring, physical therapy to regain motor skills and strength, and interventional radiology for endovascular procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult intraventricular hemorrhage market also includes sales of neuroendoscopic instruments, antiepileptic drugs, and osmotic diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.